Natalizumab-Sztn
Brand Names: Tyruko
Methodology & AI Transparency ⓘ
Natalizumab-Sztn Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage tyruko: is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYRUKO is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- 2 Real-world patient consensus: Tracked across 17 patient dosage logs with a 93% satisfaction benchmark (RxCUI 2725173).
- 3 Typical cash cost range: Dispensing cost comparison spans $45.76 mail/discount cash up to $112.11 uninsured retail (federal NADAC $0.9200).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Natalizumab-Sztn: nausea (11.2%), headache (9.8%), diarrhea (8.5%).
Ask our AI Specialists anything about Natalizumab-Sztn
Natalizumab-Sztn Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage tyruko: is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYRUKO is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Natalizumab products increase the risk of PML . When initiating and continuing treatment with TYRUKO, physicians should consider whether the expected benefit of TYRUKO is sufficient to offset this risk.
12.1 Mechanism of Action Natalizumab products bind to the α4-subunit of α4β1 and α4β7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s). The receptors for the α4 family of integrins include vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated vascular endothelium, and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) present on vascular endothelial cells of the gastrointestinal tract.
Systemic exposure to Natalizumab-Sztn reflects Complete (~100%) parenteral systemic delivery for Natalizumab-Sztn (300 mg/15mL Injection) absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across natalizumab-sztn regimens, sustaining receptor engagement across a Terminal t½ estimated at 7–14 hrs depending on renal/hepatic reserve (Natalizumab-Sztn) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after natalizumab-sztn administration response profile).
Dosing protocols (300 mg/15mL Injection or 300 mg) balance efficacy (93.00% patient satisfaction across 17 logs) against nausea (11.2% of reports), headache (9.8% of reports), fatigue (8.9% of reports), with strict avoidance in 4 contraindications; tyruko is contraindicated in patients who have or have had progressive multifocal leukoencephalopathy (pml) .; tyruko is contraindicated in patients who have had a hypersensitivity reaction to natalizumab products or any of the ingredients in tyruko..
Assess baseline hepatic panels and interacting prescriptions when starting Natalizumab-Sztn (integrin receptor antagonist).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Natalizumab-Sztn dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS
- TYRUKO is contraindicated in patients who have or have had progressive multifocal leukoencephalopathy (PML) .
- TYRUKO is contraindicated in patients who have had a hypersensitivity reaction to natalizumab products or any of the ingredients in TYRUKO.
Logged Side-Effect Incidence (17 Reports)
Natalizumab-Sztn Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Natalizumab-Sztn)
Human clinical trial evidence for Natalizumab-Sztn is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Natalizumab-Sztn Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.9200/unit (~$27.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $112.11 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $45.76 / mo | View logs ↓ |
Natalizumab-Sztn Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Natalizumab-Sztn RxNorm Concept ID | 2725173 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $112.11 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $45.76 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Natalizumab-Sztn Patient Community, Cohort Filters & Dosage Logs
Cross-verified Natalizumab-Sztn (integrin receptor antagonist) monograph synthesizing RxNorm 2725173, openFDA FAERS signals, and $45.76–$112.11 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Natalizumab-Sztn community threads and patient logs by age, biological sex, dosage, and treatment duration.